Celcuity Inc

Celcuity Inc. reports 2025 losses but strong cash reserves, keeping its high‑impact oncology drug gedatolisib on track toward $2.5 B peak revenue and regulatory milestones.

Celcuity’s Phase 3 VIKTORIA‑1 results show Gedatolisib improves PFS in PIK3CA‑wild‑type breast cancer, expanding its therapeutic reach and boosting investor confidence.

Celcuity Inc.’s (NASDAQ: CELC) stock surged nearly 48% after the company announced positive Phase III results for its investigational PI3K-targeted therapy, gedatolisib, in treating hormone-receptor-positive, HER2-negative breast cancer.

Celcuity Inc., a biotechnology company, reported a quarterly loss of $0.93 per share, exceeding market expectations and causing its stock price to decline.

Celcuity Inc. has made significant financial moves, including a $248.7 million debt and stock offering, to support its clinical trials and development of targeted therapies for breast cancer and other solid tumors.

Celcuity Inc., a clinical-stage biotech company, is poised for a potential breakthrough with the upcoming announcement of its phase 3 VIKTORIA-1 trial results, which could redefine treatment paradigms for advanced breast cancer.

Celcuity Inc. is poised for growth with a $2 billion peak revenue potential for its flagship drug gedatolisib, a promising development in the biotechnology industry.